• Consulting and advisory to medtech, biotech and digital health start-ups.

• Next generation intravascular cardiology imaging combining DeepOCT™ imaging, near infrared spectroscopy (NIRS), and AI-powered insights to optimize coronary stenting and better inform care.

• Clinical research and commercial translation strategy related to mental health, neuomodulation, addiction, and digital tools in clinical practice.

Council reviews oncology-focused grants of up to $20M/company.

• Joined as Independent Director. Became Interim CEO to build senior leadership team including CSO, CMO, and Data Science. Developed new R&D and clinical strategy.• Development stage prostate cancer prognostic for monitoring patients with low risk tumors (Active Surveillance)

Developing an ingestible drug/device which detects and reverses opioid overdose.

• Developed best practices recommendations for corporate innovation. • Evaluate technologies and manage projects that transform the treatment of neurological diseases including neuromuscular, precision psychiatry, and drug delivery.

• Non-Profit Microbiome Research Institute; Collect process, and commercial FMT for CDiff.• Oversaw clinical research, regulatory, and operations.

Clinical stage hypertension medical device.

• Managed $800M global portfolio as one of eight Managing Directors (four US MDs). Led Medtech portfolio.• Investment partner for all investment decisions across the fund globally. Mentored junior colleagues.• Sourced and invested across all therapeutic areas and modalities, including medical device, biotech, and digital. • Invested across all stages including company formation, preclinical, clinical, and commercial.• Led scientific, clinical, and financial diligence, and structured investments as lead investor. • Built syndicates up to $45M, with NVF investment up to $25M over the life of a company.• Played an integral role in portfolio company oversight: executive recruitment, clinical/commercial strategy, governance, financing events, and exit/acquisition business development and negotiation. • Developed fund best practices, related to diligence, portfolio management, and fund cash flow management.• Representative Board of Directors and portfolio engagement: Ablation Frontiers (cardiac Afib, acquired Medtronic), Autonomic Technologies (neuromodulation), Cavion (essential tremor, Acquired Jazz), Celladon (heart failure, IPO), Innocrin (oncology), Sonitus (hearing), Symetis (cardiovascular, acquired Boston Scientific), Viamet (antifungal/women’s health, acquired Novaquest), Visiogen (ophthalmology, acquired Abbott). • Recruited Entrepreneur-In-Residence and evaluated NewCo development in ophthalmology.Clinical areas including: anti-infectives, cardiology, diabetes, diagnostics, immunology, otology, ophthalmology, oncology, respiratory, and neuroscience.

• Led diligence and investment in medical device companies as part of four-person life sciences team.• Board and portfolio engagement: Insulet (PODD), iScience (glaucoma), Songbird Hearing (hearing aids), Confirma (breast MRI imaging), Cortek (orthopedics), Sensitech (cold chain, acquired Carrier/UTX), MedManage (pharma sampling), and Coaxia (stroke). Prism managed $1.25B, and made investments of up to $20M.

• Managed the diligence, negotiation and deal execution of six Series A investments. • Served as board observer on seven portfolio companies from R&D to $20M+ revenue.Mid-Atlantic Venture Funds managed $200M, and was an early stage venture capital investor in software companies.